key: cord-0841495-99tzxwfh authors: Brown, A.; Shah, S.; Dluzewski, S.; Musaddaq, B.; Wagner, T.; Szyszko, T.; Wan, S.; Groves, A.; Mokbel, K.; Malhotra, A. title: Unilateral axillary adenopathy following COVID-19 vaccination: a multimodality pictorial illustration and review of current guidelines date: 2021-05-14 journal: Clin Radiol DOI: 10.1016/j.crad.2021.04.010 sha: a66c92543d458da70ab5918a73cd536e88518d4f doc_id: 841495 cord_uid: 99tzxwfh We present a multimodality pictorial review of axillary lymphadenopathy in patients recently vaccinated against COVID-19. As the mass vaccination programme continues to be rolled out worldwide in an effort to combat the pandemic, it is important that radiologists consider recent COVID-19 vaccination in the differential diagnosis of unilateral axillary lymphadenopathy and are aware of typical appearances across all imaging methods. We review current guidelines on the management of unilateral axillary lymphadenopathy in the context of recent COVID-19 vaccination. to <1% of patients), 1,2 their widespread use has resulted in benign unilateral axillary lymphadenopathy becoming an increasingly encountered side effect. 3, 4 Although the link between vaccination and unilateral axillary lymphadenopathy and vaccination is not new 5, 6, 7 , early experiences show that the incidence is higher with the COVID-19 vaccine compared to other vaccines as it invokes a strong immune response. 8 This review aims to demonstrate the imaging appearances of benign reactive hyperplasia across various imaging techniques in patients with a recent history of COVID-19 vaccination. We will then discuss current guidelines and management strategies. The patients in this series were selected from two institutions in January and February 2021, shortly after the vaccination programme commenced. The cases include patients with a known malignancy who underwent staging or surveillance J o u r n a l P r e -p r o o f imaging, as well as patients without a history of malignancy presenting to symptomatic breast clinic. Ultrasound offers the most thorough assessment of the size and morphology of axillary lymph nodes due to its high soft-tissue resolution. Axillary lymphadenopathy post-COVID-19 vaccination may be discovered as part of assessment of a palpable axillary lump or as an incidental finding, for example, as part of breast ultrasound. In the latter, this may cause a diagnostic conundrum as other differentials include metastases from breast cancer. Sonographic appearances of COVID-19 vaccine-related lymphadenopathy are nonspecific and include lymph node enlargement as measured by increased short-axis diameter, a thickened cortex (Figs. 1-3) and loss of the normal fatty hilum (Fig. 4) . The affected lymph node may be hypervascular on colour Doppler (Fig. 1b) . The contralateral axillary lymph nodes should be of normal size in the absence of concurrent pathology. The avid nodes may be single or multiple, as in Fig. 5 . Hypermetabolic nodes may also be seen in the subpectoral region, as in Fig. 6 . On the CT component, the hypermetabolic nodes may be enlarged, as in Fig. 7 , or may be within normal size limits. An important finding that indicates the hypermetabolic lymph node is likely to be vaccine related is the synchronous finding of hypermetabolic inflammation in the ipsilateral deltoid muscle, corresponding to the site of injection, as seen in Figs. 6 and 8. In Fig. 7 , the FDG-uptake within the axillary lymph node persisted for almost 3 weeks. Other early data have shown this to persist beyond 5 weeks postinjection, 9 and to last longer after the second vaccine dose. 10 MAGNETIC RESONANCE IMAGING COVID-19 vaccine-related axillary lymphadenopathy is detected much less commonly on magnetic resonance imaging (MRI) than on ultrasound and CT due to the lower number of MRI studies performed. It may be detected on imaging of the breasts, thorax, or musculoskeletal MRI of the upper limbs. Findings are again nonspecific, including axillary lymph nodes with a thickened cortex, which may or not be enlarged. There may be increased signal on T2 and short-tau inversion recovery (STIR) sequences in the ipsilateral deltoid muscle and overlying skin corresponding to oedema secondary to local inflammation at the injection site. This would increase confidence that any lymphadenopathy was vaccine related. It is likely that axillary lymphadenopathy will be seen more frequently on breast MRI compared to mammography as it provides greater visualisation of the axillary node J o u r n a l P r e -p r o o f basin. In Fig. 9 , the initial breast MRI, which detected a new right breast malignancy, showed no lymphadenopathy; however, the follow-up ultrasound showed an enlarged ipsilateral axillary node ( CT is, however, less sensitive at detecting COVID-19-related axillary lymphadenopathy than PET/CT, as shown in Fig. 6 , increased FDG uptake may be seen in non-enlarged lymph nodes that appear normal on CT. The present review is a multi-modality pictorial illustration of unilateral axillary lymphadenopathy in patients who had received their COVID-19 vaccination in the ipsilateral arm several days to several weeks prior to imaging. This is an increasingly common finding as more of the population receives their COVID-19 vaccine. The differential for unilateral axillary lymphadenopathy is wide and includes breast cancer as the most common malignant differential, as well as a range of benign causes such as infection, inflammation, or trauma to the ipsilateral breast, arm and J o u r n a l P r e -p r o o f chest wall, as well as recent vaccination. A particular diagnostic challenge is encountered when this finding is detected in patients with a history of breast cancer due to the concern of metastatic disease. National Institute for Health and Care Excellence (NICE) guidance for assessment of enlarged axillary nodes advocates a "watch and wait" approach, with referral to a specialist if persistent at 6 weeks. This guidance has not changed in light of the UK Government Regulatory Approval Decision Statement UK Government Regulatory Approval Decision Statement Lymphadenopathy in COVID-19 vaccine recipients: diagnostic dilemma in oncology patients Infectious diseases Development of unilateral cervical and supraclavicular lymphadenopathy after human papilloma virus vaccination FDG uptake in axillary lymph nodes after vaccination against pandemic (H1N1)